US 11,752,192 B2
Inhibitor of RNA polymerase II
Catharina Svanborg, Malmo (SE); Nina Filenko, Lund (SE); and Ines Ambite, Lund (SE)
Filed by SELECTIMMUNE PHARMA AB, Lund (SE)
Filed on Sep. 25, 2020, as Appl. No. 17/32,308.
Application 17/032,308 is a division of application No. 16/341,962, abandoned, previously published as PCT/IB2017/056413, filed on Oct. 16, 2017.
Claims priority of application No. 1617548 (GB), filed on Oct. 17, 2016.
Prior Publication US 2021/0069291 A1, Mar. 11, 2021
Int. Cl. A61K 38/16 (2006.01); A61K 35/74 (2015.01); G01N 33/573 (2006.01); A61K 38/44 (2006.01)
CPC A61K 38/164 (2013.01) [A61K 35/74 (2013.01); A61K 38/443 (2013.01); G01N 33/573 (2013.01); G01N 2333/91255 (2013.01); Y02A 50/30 (2018.01)] 15 Claims
 
1. A method for providing immunosuppression, anti-inflammatory, or anti-infection therapy to a patient in need therefore, the method comprising administering to the patient a pharmaceutical composition comprising an effective amount of an inhibitor of RNA polymerase II, wherein said inhibitor is
(a) an E. coli NlpD protein; or
(b) an active variant of an E. coli NlpD protein having an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 4; or
(c) an E. coli Sigma S protein; or
(d) an active variant of an E. coli Sigma S protein having an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; or
(e) an active fragment of (a), (b), (c), or (d).